Korean J Endocr Surg.  2015 Jun;15(2):25-33. 10.16956/kaes.2015.15.2.25.

Prognostic Value of p53 and Cyclin D1 in Papillary Thyroid Carcinoma

• Seok JY
• Chung DH
• Chung YS
• Ryu JW
• Lee YD

• KMID: 2144002
• DOI: http://doi.org/10.16956/kaes.2015.15.2.25

Abstract

PURPOSE
P53 and cyclin D1 have been evaluated as a prognostic marker in papillary thyroid carcinoma (PTC). However, the relationship between p53/cyclin D1 and PTC prognosis has not yet been confirmed. Therefore, we investigated the relationship between p53/cyclin D1 and PTC prognostic factors.
METHODS
919 patients with PTC were enrolled. Immunohistochemistry slides were reviewed for p53 and cyclin D1 immunoreactivity. Patients were classified into two groups according to the p53 and cyclin D1 grade: negative for < or =5% and positive for >5%. Medical records were reviewed to evaluate the prognostic factors, lymph node metastatic ratio (LNMR), and MACIS score. We analyzed patients based on p53/cyclin D1(-/-), p53/cyclin D1(-/+), p53/cyclin D1(+/-), p53/cyclin D1(+/+) separately for evaluation of independent effect of p53 and cyclin D1.
RESULTS
Mean age of the patients was 49.73 years (range 15~87), and tumor size was 1.19 cm (range 0.1~5.0). P53 was positive in 809 (88.0%) and cyclin D1 was positive in 748 (81.4%). Positivity of p53 and cyclin D1 were correlated (r=0.448). There was no statistical significance in MACIS score. Positivity of p53 and cyclin D1 were related with larger tumor size, older age, early T stage, more tumor capsulation, and female. LNMR was higher in p53/cyclin D1(+/-) than p53/cyclin D1(-/-) (P=0.036), p53/cyclin D1(-/+) than p53/cyclin D1(-/-) (P=0.034), and p53/cyclin D1(+/+) than p53/cyclin D1(-/-) (P=0.007).
CONCLUSION
There was no consistent relationship between p53/cyclin D1 and worse prognostic factors of PTC. However, LNMR was higher in p53(+) and cyclin D1(+) cases independently, much more in p53/cyclin D1(+/+) than p53/cyclin D1(-/-).

Keyword

Papillary thyroid carcinoma; p53; Cyclin D1; Prognosis; Lymph node metastatic ratio

MeSH Terms

Cyclin D1*
Cyclins
Female
Humans
Immunohistochemistry
Lymph Nodes
Medical Records
Prognosis
Thyroid Neoplasms*
Cyclin D1
Cyclins

Figure

• 

  Fig. 1. IHC stain of p53 and cyclin D1 in PTC. Typical histology of inclusion bodies and nuclear groove (A, ×200). IHC of p53 detected in nuclei of multiple tumor cells (B, ×200). Cyclin D1 were detected diffusely in nuclei and cytoplasm of tumor cells (C, ×200).

Reference

References

1. Omur O, Baran Y. An update on molecular biology of thyroid cancers. Crit Rev Oncol Hematol. 2014; 90:233–52.

2. Zafon C, Obiols G, Castellví J, Tallada N, Baena JA, Simó R, et al. Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology. 2007; 50:225–31.

3. Karlidag T, Cobanoglu B, Keles E, Alpay HC, Ozercan I, Kaygusuz I, et al. Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol. 2007; 28:31–6.

4. Morita N, Ikeda Y, Takami H. Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg. 2008; 32:2617–22.

5. Balta AZ, Filiz AI, Kurt Y, Sucullu I, Yucel E, Akin ML. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma. Med Oncol. 2012; 29:734–41.

6. Kim BS, Kang KH, Lim YA, Kim LS. Clinical significance of p53, ki-67 and galectin-3 expressions in papillary thyroid carcinoma. J Korean Surg Soc. 2009; 77:29–36.

7. Ji WB, Bae JW, Woo SU, Son GS, Lee JB, Koo BW, et al. The significance of bcl-2 and p53 expressions in the papillary thyroid cancer. Korean J Endocr Surg. 2007; 7:231–6.

8. Lee SH, Park SY, Kim NR, Lee YD. The expressions of CK7, CK20, vimentin, p53 and ki-67 in papillary thyroid carcinoma. Korean J Endocr Surg. 2009; 9:7–13.

9. Lee YM, Lee JB. Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma. J Int Med Res. 2013; 41:825–34.

10. Shin MK, Kim JW. Clinicopathologic and diagnostic significance of p53 protein expression in papillary thyroid carcinoma. Asian Pac J Cancer Prev. 2014; 15:2341–4.

11. Basolo F, Caligo MA, Pinchera A, Fedeli F, Baldanzi A, Miccoli P, et al. Cyclin D1 overexpression in thyroid carcinomas: relation with clinicopathological parameters, retinoblastoma gene product, and Ki67 labeling index. Thyroid. 2000; 10:741–6.

12. Temmim L, Ebraheem AK, Baker H, Sinowatz F. Cyclin D1 protein expression in human thyroid gland and thyroid cancer. Anat Histol Embryol. 2006; 35:125–9.

13. Lee SH, Lee JK, Jin SM, Lee KC, Sohn JH, Chae SW, et al. Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma. Otolaryngol Head Neck Surg. 2010; 142:332–7.

14. Kim HJ, Kim YS, Kim SW, Kim KC. Expression of cyclin d1, cytokeratin 7, cytokeratin 20 and vimentin in papillary thyroid cancer and relationship with patient's prognostic factors. Korean J Endocr Surg. 2012; 12:92–7.

15. Melck A, Masoudi H, Griffith OL, Rajput A, Wilkins G, Bugis S, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol. 2007; 14:3403–11.

16. Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol. 2003; 23:4713–27.

17. Ullmannová V, Stöckbauer P, Hradcová M, Soucek J, Haskovec C. Relationship between cyclin D1 and p21 (Waf1/Cip1) during differentiation of human myeloid leukemia cell lines. Leuk Res. 2003; 27:1115–23.

18. Pines J. Four-dimensional control of the cell cycle. Nat Cell Biol. 1999; 1:E73–9.

19. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993; 114:1050–7.

20. Marcello MA, Morari EC, Ward LS. P53 protein profile by IHC may be helpful to define patient prognosis. Med Oncol. 2012; 29:2309–10.

21. Londero SC, Godballe C, Krogdahl A, Bastholt L, Specht L, Sørensen CH, et al. Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease? Acta Oncol. 2008; 47:451–7.

22. Lantsov D, Meirmanov S, Nakashima M, Kondo H, Saenko V, Naruke Y, et al. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology. 2005; 47:248–56.

23. Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2002; 87:1814–8.

24. Pesutić-Pisac V, Punda A, Gluncić I, Bedeković V, Pranić-Kragić A, Kunac N. Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters. Croat Med J. 2008; 49:643–9.

25. Ioachim E. Expression patterns of cyclins D1, E and cyclindependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Int J Clin Pract. 2008; 62:1736–43.

26. Oh YL, Choi JS, Song SY, Ko YH, Han BK, Nam SJ, et al. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int. 2001; 51:94–9.

27. Raju B, Mehrotra R, Oijordsbakken G, Al-Sharabi AK, Vasstrand EN, Ibrahim SO. Expression of p53, cyclin D1 and Ki-67 in premalignant and malignant oral lesions: association with clinicopathological parameters. Anticancer Res. 2005; 25:4699–706.

28. Ryu IS, Song CI, Choi SH, Roh JL, Nam SY, Kim SY. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann Surg Oncol. 2014; 21:277–83.

29. Jeon MJ, Yoon JH, Han JM, Yim JH, Hong SJ, Song DE, et al. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur J Endocrinol. 2013; 168:219–25.

30. Lang BH, Wong KP, Wan KY, Lo CY. Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. Ann Surg Oncol. 2012; 19:1257–63.